SMSaloni Mangal

Saloni Mangal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saloni Mangal has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Avijit Mazumder

    Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India

    2 shared publications
  • Salahuddin Salahuddin

    Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida 201306, Uttar Pradesh, India

    2 shared publications
  • Abhijit Debnath

    Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, 201310, India

    1 shared publication
  • Anil Kumar Singh

    Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

    1 shared publication
  • Avijit Mazumder

    Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Plot no.19, Knowledge Park-2, Greater Noida, 201306, Uttar Pradesh, India

    1 shared publication
  • Hema Chaudhary

    School of Medical & Allied Sciences, K R Mangalam University, Gurugram, India

    1 shared publication

Latest Publications

  • Optimized Strategies for the Synthesis and Structure-Activity Relationship of Imidazole as an Antiepileptic Drug

    by Saloni Mangal, Salahuddin, Avijit Mazumder, Rajnish Kumar, Sapna Rani, Vimal Datt, Mohamed Jawed Ahsan, Mohammad Shahar Yar

    Imidazole is believed to be a highly multifunctional compound in the medicinal andbiological sectors. This literature focuses on information about the synthesis and anticonvulsantactivity presented by the imidazole nucleus. Epilepsy is a chronic brain disorder including multipleseizures and brain cell abnormalities. Due to its old and less effective treatment, with theincrease in the number of patients suffering from epilepsy, researchers need to concentrate onthe emergence of finding new treatments for epilepsy. Imidazole-containing analogs are foundto be significant in the field of medicinal chemistry and the treatment for epilepsy. These studiesprompted us to synthesize and provide insights into developing new imidazole-bearing antiepilepticdrugs.

  • Significant advances in catalytic strategies for the synthesis of trisubstituted imidazoles: a review

    by Saloni Mangal, Salahuddin, Avijit Mazumder, Rajnish Kumar, Sapna Rani, Mohamed Jawed Ahsan, Mohammad Shahar Yar


  • Quest for discovering novel CDK12 inhibitor

    by Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Avijit Mazumder, Shikha Srivastava, Hema Chaudhary, Saloni Mangal, Jahanvi Sanchitra, Pankaj Kumar Tyagi, Sachin Kumar Singh, et al.

    CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Consequently, this research aims to identify effective CDK12 inhibitors using comprehensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, MD Simulation, and in-vitro studies MTT assay. The research conducted yielded one compound ZINC11784547 has demonstrated robust binding affinity, favorable ADME features, less toxicity, remarkable stability, and cytotoxic effect. The identified compound holds promise for promoting cancer cell death through CDK12 inhibition.